RNA-seq analysis of MEK or ERK1/2 inhibitor treatment in uveal melanoma cell lines.
Activating GNAQ/GNA11 are present in majority of uveal melanomas resulting in downstream activation of the MAPK pathway. To elucidate changes in the transcriptome after MEK or ERK1/2 inhibition, we performed RNA sequencing on two UM cell lines. Differential analysis revealed that MARK3 expression was not altered but STK10 expression was reduced. Overall design: RNA was obtained from PDX4 and UM004 after drug treatment for 24 hours in uveal melanoma cell lines.